For example, Den Uil et al. argued that contradictory studies on CDX2 may have arisen from using IHC to determine CDX2 levels in CRC-II patients’ samples instead of mass spectrometry (MS) [101]. This evidence concerns the gene CDX2 and colorectal carcinoma.